2. >>Products
  3. >>Generics

Five More Circle Tecfidera With Ruling 'Unlikely To Be Reversed'

Delaware Decision Allows ANDA Sponsors To Launch

 
• By Dean Rudge

With a federal district court decision opening the door for a multitude of generic Tecfidera products, the market has reacted, suggesting as many as five ANDA products are primed for launch.

Target
As many as five Tecfidera ANDA sponsors are targeting launch, it has been claimed • Source: Shutterstock

The US market for Biogen’s Tecfidera (dimethyl fumarate) blockbuster is to be commoditized, with four or five additional generic sponsors now seeking final approval and launch following a Delaware district court decision that has paved the way for further competition, a US healthcare investor has claimed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

More from Products